Discover more
than you think

Developing innovative cancer treatments tackling GPCR mediated-immunosuppression

About us

Immuno-oncology
programs

We are advancing multiple first-in-class and best-in class programs to tackle GPCR-mediated immunosuppression in immune-oncology 

Learn more

Immuno-oncology pipeline
Name Discovery Candidate Preclinical Clinical Partner
A2aR/A2bR antagonist Preclinical MERCK
EP4R antagonist (DT-9081) Preclinical
anti-CCR8 antibody Discovery
Undisclosed GPCR targets Discovery

Our unique
positioning

We build a high value pipeline focused on GPCRs to rearm immune system against tumors.                                                                 

Approach
GPCRs & IO